These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 29363464)

  • 1. Diminished emotional expression in schizophrenia: an interdisciplinary approach based on behavioral interventions.
    González-Pando D; Alonso-Pérez F; Suárez-Gil P; García-Montes JM; Pérez M
    Psicothema; 2018 Feb; 30(1):8-13. PubMed ID: 29363464
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Positive Emotions Program for Schizophrenia (PEPS): a pilot intervention to reduce anhedonia and apathy.
    Favrod J; Nguyen A; Fankhauser C; Ismailaj A; Hasler JD; Ringuet A; Rexhaj S; Bonsack C
    BMC Psychiatry; 2015 Sep; 15():231. PubMed ID: 26419356
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Facial expressiveness in patients with schizophrenia compared to depressed patients and nonpatient comparison subjects.
    Trémeau F; Malaspina D; Duval F; Corrêa H; Hager-Budny M; Coin-Bariou L; Macher JP; Gorman JM
    Am J Psychiatry; 2005 Jan; 162(1):92-101. PubMed ID: 15625206
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recognizing primary vs secondary negative symptoms and apathy vs expression domains.
    Kirkpatrick B
    J Clin Psychiatry; 2014 Apr; 75(4):e09. PubMed ID: 24813410
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [A critical study of the influence of negative symptoms on the therapeutic response in schizophrenia].
    Acuña MJ; Martín J; Noval D; Blanco M
    Actas Luso Esp Neurol Psiquiatr Cienc Afines; 1998; 26(4):209-13. PubMed ID: 9807853
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Individual negative symptoms and domains - Relevance for assessment, pathomechanisms and treatment.
    Kaiser S; Lyne J; Agartz I; Clarke M; Mørch-Johnsen L; Faerden A
    Schizophr Res; 2017 Aug; 186():39-45. PubMed ID: 27453425
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Negative symptoms in schizophrenia - overview and practical implications].
    Klaus F; Dorsaz O; Kaiser S
    Rev Med Suisse; 2018 Sep; 14(619):1660-1664. PubMed ID: 30230774
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Affective flattening and the criteria for schizophrenia.
    Andreasen NC
    Am J Psychiatry; 1979 Jul; 136(7):944-7. PubMed ID: 453357
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Evaluation of the emotional blunting and its prognostic importance during neuroleptic treatment of schizophrenia].
    Kukulska D
    Psychiatr Pol; 2003; 37(6):999-1012. PubMed ID: 14727372
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathophysiology of negative symptom dimensions of schizophrenia - Current developments and implications for treatment.
    Bègue I; Kaiser S; Kirschner M
    Neurosci Biobehav Rev; 2020 Sep; 116():74-88. PubMed ID: 32533996
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Evolution of the concept of apathy: the need for a multifactorial approach in schizophrenia].
    Del-Monte J; Capdevielle D; Gély-Nargeot MC; Yazbek H; Pupier F; Boulenger JP; Raffard S
    Encephale; 2013 May; 39 Suppl 1():S57-63. PubMed ID: 23351930
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Zotepine versus placebo in the treatment of schizophrenic patients with stable primary negative symptoms: a randomized double-blind multicenter trial.
    Möller HJ; Riedel M; Müller N; Fischer W; Kohnen R
    Pharmacopsychiatry; 2004 Nov; 37(6):270-8. PubMed ID: 15551193
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The location of the deficits of emotional communication in dimensional models of schizophrenia].
    Kucharska-Pietura K; Masiak M
    Psychiatr Pol; 2004; 38(5):809-18. PubMed ID: 15523928
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Negative symptoms: a path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine.
    Tollefson GD; Sanger TM
    Am J Psychiatry; 1997 Apr; 154(4):466-74. PubMed ID: 9090332
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The clinic of apathy in schizophrenia: a critical review of the issue].
    Yazbek H; Raffard S; Del-Monte J; Pupier F; Larue A; Boulenger JP; Gély-Nargeot MC; Capdevielle D
    Encephale; 2014 Jun; 40(3):231-9. PubMed ID: 23958346
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Negative symptoms in schizophrenia: psychotherapeutic approaches].
    Azorin JM; Adida M; Belzeaux R; Pringuey D; Micoulaud Franchi JA; Simon N; Cermolacce M; Kaladjian A; Fakra E
    Encephale; 2015 Dec; 41(6 Suppl 1):6S57-60. PubMed ID: 26776394
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A multisite investigation of the reliability of the Scale for the Assessment of Negative Symptoms.
    Mueser KT; Sayers SL; Schooler NR; Mance RM; Haas GL
    Am J Psychiatry; 1994 Oct; 151(10):1453-62. PubMed ID: 7916540
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emotion word use in the conversational speech of schizophrenia patients.
    St-Hilaire A; Cohen AS; Docherty NM
    Cogn Neuropsychiatry; 2008 Jul; 13(4):343-56. PubMed ID: 18622789
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study.
    Lane HY; Chang YC; Liu YC; Chiu CC; Tsai GE
    Arch Gen Psychiatry; 2005 Nov; 62(11):1196-204. PubMed ID: 16275807
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of negative symptoms in outpatients with schizophrenia spectrum disorders treated with antipsychotics in routine clinical practice: findings from the CLAMORS study.
    Bobes J; Arango C; Garcia-Garcia M; Rejas J;
    J Clin Psychiatry; 2010 Mar; 71(3):280-6. PubMed ID: 19895779
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.